Clatterbridge Cancer Centre NHS Foundation Trust

Replimune Presents Updated Data on RP2 in Uveal Melanoma during Plenary Session at the 20th International Congress of the Society for Melanoma Research

Retrieved on: 
Wednesday, November 8, 2023
Survival, FRCP, Research, Uveal melanoma, International Congress on Tuberculosis, Trae tha Truth, Nivolumab, University of Liverpool, Bachelor of Medicine, Bachelor of Surgery, DOR, Melanoma, Liver, Clatterbridge Cancer Centre NHS Foundation Trust, Doctor of Philosophy, Ipilimumab, Development, Lung, 8th Plenary Session of the Central Committee of the League of Communists of Serbia, Disease, Hypotension, Liver disease, Metastasis, RP2, Itch, Uvea, Immunotherapy, ORR, Chills, University, Society, Melanoma Research, Patient, Toxicity, Fatigue, Pharmaceutical industry, Fever

The data were presented by Dr. Joseph Sacco during a Plenary Session at the 20th International Congress of the Society for Melanoma Research in Philadelphia.

Key Points: 
  • The data were presented by Dr. Joseph Sacco during a Plenary Session at the 20th International Congress of the Society for Melanoma Research in Philadelphia.
  • The median duration of response (DOR) at the data cutoff was 11.47 months (range of 2.78 to 21.22 with responses ongoing).
  • RP2 was generally well tolerated both as monotherapy and in combination with nivolumab with no additive adverse events observed.
  • “These data from the trial cohort evaluating RP2 as monotherapy and in combination with nivolumab in metastatic uveal melanoma are highly promising,” said Robert Coffin, President and Chief Research & Development Officer at Replimune.

Sun Nuclear Showcases Evolving and Expanding Quality Management Portfolio at ESTRO 2023 Meeting

Retrieved on: 
Friday, May 12, 2023
GE HealthCare, CIRS, Clatterbridge Cancer Centre NHS Foundation Trust, User-centered design, Radiation, Quality management, GE, Emerging, EPID, Ultrasound, MR, Radiation therapy, Medical imaging, Motion, Gold, QA, MIR, IVD, Ecosystem, Yellow Sun (nuclear weapon), VMAT, News, NYSE, Safety

MELBOURNE, Fla., May 12, 2023 /PRNewswire/ -- Sun Nuclear, a Mirion Medical company (Mirion, NYSE: MIR), will highlight the latest innovations for Quality Management at the ESTRO Annual Meeting beginning Friday, May 12, in Vienna, Austria. Industry gold standard and novel Radiation Therapy and Diagnostic Imaging QA solutions will be featured in ESTRO booth #150 throughout the meeting, with product demonstrations and user presentations.

Key Points: 
  • MELBOURNE, Fla., May 12, 2023 /PRNewswire/ -- Sun Nuclear , a Mirion Medical company (Mirion, NYSE: MIR), will highlight the latest innovations for Quality Management at the ESTRO Annual Meeting beginning Friday, May 12, in Vienna, Austria.
  • On Sunday, May 14, Sun Nuclear will hold its annual lunch symposium, featuring insights from leaders in the field of Radiation Therapy.
  • Automated, Integrated Quality Management: The SunCHECK Platform powers Quality Management, with centralized, standardized Patient and Machine QA for Radiation Therapy programs.
  • ESTRO attendees will notice new branding reflected in the Sun Nuclear booth and the inclusion of CIRS solutions, which are now part of the Sun Nuclear brand.

The UK Medicines and Healthcare products Regulatory Agency (MHRA), Australian Therapeutic Goods Administration (TGA) and Health Canada approve KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma

Retrieved on: 
Wednesday, June 8, 2022
TCR, Oncology, Itch, Fever, Adult, Therapeutic Goods Administration, Cancer, CD3, Survival, HIV disease progression rates, Food, Toxicity, TGA, MHRA, United, EC, Health care, CEO, Nasdaq, Regius, University, Autoimmunity, Pembrolizumab, Dacarbazine, Health Canada, Clatterbridge Cancer Centre NHS Foundation Trust, The New England Journal of Medicine, Patient, Infection, Uveal melanoma, Pascal (microarchitecture), Clinical trial, CRS, Royal commission, Population, Medicines and Healthcare products Regulatory Agency, European Commission, Consultant, Rash, OS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Ipilimumab, Pharmaceutical industry, Immunocore, Mum, Medicine

Marketing authorization by the MHRA, TGA, and Health Canada follows recent approvals from both the U.S. Food and Drug Administration and the European Commission (EC).

Key Points: 
  • Marketing authorization by the MHRA, TGA, and Health Canada follows recent approvals from both the U.S. Food and Drug Administration and the European Commission (EC).
  • Data from the trial, the largest Phase 3 trial undertaken in mUM, showed that KIMMTRAK demonstrated unprecedented median OS benefit as a first-line treatment.
  • Susanna Daniels, CEO of Melanoma Focus, said: This is a first for patients with metastatic uveal melanoma, who now have a licensed treatment available.
  • Unresectable or metastatic uveal melanoma typically has a poor prognosis and had no approved treatment until KIMMTRAK.

Transgene to Present Updated Positive Preliminary Data from the Phase I Clinical Trials with TG4050 (myvac® platform) at ASCO 2022

Retrieved on: 
Friday, May 27, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Other Health, Department, Disease, Immunotherapy, Drug development, Neoplasm, Mayo Clinic, AI, Doctor of Philosophy, AstraZeneca, Patient, AMF, Bachelor of Engineering, Associate, Clinical trial, Society, American Society of Clinical Oncology, Clinical professor, Marketing, Clatterbridge Cancer Centre NHS Foundation Trust, TNG, NEC, Artificial intelligence, Vaccination, Curie Institute (Paris), Recurrence, Forward-looking statement, University, Safety, ASCO, Euronext Paris, Ovarian cancer, Immune system, Twitter, MVA, Precision medicine, Cancer, Potyvirus, MD, Risk, Pharmaceutical industry, Vaccine, Euronext, Transgene

The abstract reports positive immunogenicity and clinical data generated from the two ongoing Phase I trials in patients with ovarian cancer and HPV-negative head and neck cancer (NCT03839524 and NCT04183166).

Key Points: 
  • The abstract reports positive immunogenicity and clinical data generated from the two ongoing Phase I trials in patients with ovarian cancer and HPV-negative head and neck cancer (NCT03839524 and NCT04183166).
  • The detailed data will be presented during a poster session on June 5, 2022, at the ASCO conference.
  • In a first Phase I trial, TG4050 is being administered to patients with HPV-negative head and neck cancer.
  • This randomized study is evaluating the treatment benefits of TG4050 in patients who have a high risk of relapse.

Transgene to Present New Positive Preliminary Phase I Data on TG4050 (myvac® platform), its Individualized Therapeutic Cancer Vaccine, at AACR 2022

Retrieved on: 
Wednesday, March 9, 2022
Research, Medical Supplies, Hospitals, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, Online, University, Euronext Paris, Artificial intelligence, AstraZeneca, Precision medicine, AM, Section 33 of the Canadian Charter of Rights and Freedoms, Disease, Poster, Safety, MVA, Marketing, Immune system, AI, Curie Institute (Paris), Ovarian cancer, Clatterbridge Cancer Centre NHS Foundation Trust, Doctor of Philosophy, Patient, Neoplasm, Bronx Community Board 7, Recurrence, American Association for Cancer Research, Time, Head, Clinical trial, Bachelor of Engineering, Cancer, MD, Risk, Mayo Clinic, Clinical professor, Forward-looking statement, AACR, Department, TNG, NEC, Potyvirus, AMF, Vaccination, Board, Drug development, American Association, Immunotherapy, Associate, Vaccine, Pharmaceutical industry, Transgene, Euronext

Powered by NECs cutting-edge AI capabilities, TG4050 is being evaluated in two ongoing multicenter Phase I trials in patients with ovarian cancer and head and neck cancer.

Key Points: 
  • Powered by NECs cutting-edge AI capabilities, TG4050 is being evaluated in two ongoing multicenter Phase I trials in patients with ovarian cancer and head and neck cancer.
  • Date, time, location: Tuesday Apr 12, 2022 9:00 AM - 12:30 PM CDT, Board 7, Section 33
    In a first Phase I trial, TG4050 is being administered to patients with HPV-negative head and neck cancer.
  • A personalized treatment is created for each patient after they complete surgery and while they receive an adjuvant therapy.
  • The other half is given TG4050 as an additional treatment at the time of recurrence of the disease.

VitalHub Announces Deployment of Intouch with Health’s Solution to Major New Cancer Hospital, Clatterbridge Cancer Centre, Liverpool

Retrieved on: 
Wednesday, September 16, 2020
NHS Foundation Trusts, Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge, Health in England, Merseyside, Counties of England, Clatterbridge Health Park

TORONTO, Sept. 16, 2020 (GLOBE NEWSWIRE) -- VitalHub Corp. (the Company or VitalHub) (TSXV: VHI) is pleased to announce the deployment of newly-acquired Intouch with Healths digital patient flow solution at newly-built Clatterbridge Cancer Centre Liverpool (CCC-L or Clatterbridge).

Key Points: 
  • TORONTO, Sept. 16, 2020 (GLOBE NEWSWIRE) -- VitalHub Corp. (the Company or VitalHub) (TSXV: VHI) is pleased to announce the deployment of newly-acquired Intouch with Healths digital patient flow solution at newly-built Clatterbridge Cancer Centre Liverpool (CCC-L or Clatterbridge).
  • The new Clatterbridge Cancer Centre Liverpool (CCC-L) is a major new hospital that will transform cancer care in one of the worst-affected areas of the UK, and is part of The Clatterbridge Cancer Centre NHS Foundation Trust.
  • Clatterbridge has deployed VitalHubs newly acquired Intouch with Healths digital patient flow solution, to help improve the patient experience and drive efficiency across its cancer clinics.
  • Clatterbridge, an 11-storey hospital, is part of a 162m investment in transforming cancer services across Cheshire and Merseyside.

The Clatterbridge Cancer Centre Joins Reference Site Roster for Sun Nuclear's SunCHECK™ Enterprise Quality Management Platform

Retrieved on: 
Thursday, October 11, 2018
NHS Foundation Trusts, Clatterbridge Cancer Centre NHS Foundation Trust, Merseyside, Medical physics, Health in England, Counties of England, Clatterbridge, Radiation therapy, Clatterbridge Health Park

MELBOURNE, Fla., Oct. 11, 2018 /PRNewswire-PRWeb/ -- Sun Nuclear Corporation announced today that The Clatterbridge Cancer Centre NHS Foundation Trust has signed on as a reference site for its SunCHECK Quality Management Platform .

Key Points: 
  • MELBOURNE, Fla., Oct. 11, 2018 /PRNewswire-PRWeb/ -- Sun Nuclear Corporation announced today that The Clatterbridge Cancer Centre NHS Foundation Trust has signed on as a reference site for its SunCHECK Quality Management Platform .
  • In partnering with Sun Nuclear as a SunCHECK reference site, The Clatterbridge Cancer Centre will support development of best practices for clinical use, advise on ongoing platform development, and serve as a regional resource for a rapidly-growing community of SunCHECK users.
  • SunCHECK is an integrated, independent enterprise software solution featuring automation and direct quality assurance (QA) device connectivity for radiation therapy.
  • The Clatterbridge Cancer Centre, with 10 Varian radiation therapy delivery systems across two sites in northwest England, selected SunCHECK as its Quality Management Platform.